Q-omics provides the consensus-scored LIN9 profile across patient tissues and cancer cell-line models. LIN9 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LIN9 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, LIN9 RNA expression shows 23,543 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, BLCA, and LSCC as cancer lineages where LIN9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LIN9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LIN9 survival associations across molecular data types. LIN9 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LIN9 RNA expression–survival associations across cancer types. High LIN9 expression shows unfavorable associations in ACC, LIHC, KICH, KIRP and UVM, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LIN9 RNA expression.
This table summarizes LIN9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LIN9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LIN9 shows higher tumor expression in BLCA, HNSC, LIHC, LUAD, STAD and COAD. The BLCA box plot shows higher LIN9 RNA expression in tumor versus normal tissue (log2 FC = +1.342, t-test p < 0.001).
This table shows molecular features associated with LIN9 in patient tissues and cancer cell lines. In patient samples, LIN9 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, LIN9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
